<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: China Makes Significant Commitments to Improve Intellectual Property Protection in Phase 1 Trade Deal	</title>
	<atom:link href="https://www.chinaiplawupdate.com/2020/01/china-makes-significant-commitments-to-improve-intellectual-property-protection-in-phase-1-trade-deal/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.chinaiplawupdate.com/2020/01/china-makes-significant-commitments-to-improve-intellectual-property-protection-in-phase-1-trade-deal/</link>
	<description></description>
	<lastBuildDate>Mon, 08 Mar 2021 05:11:28 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.5.2</generator>
	<item>
		<title>
		By: China&#039;s Supreme People&#039;s Court Releases Provisions on Several Issues Concerning the Application of Law in the Trial of Administrative Cases Concerning Patent Grant and Confirmation - China IP Law Update		</title>
		<link>https://www.chinaiplawupdate.com/2020/01/china-makes-significant-commitments-to-improve-intellectual-property-protection-in-phase-1-trade-deal/#comment-52</link>

		<dc:creator><![CDATA[China&#039;s Supreme People&#039;s Court Releases Provisions on Several Issues Concerning the Application of Law in the Trial of Administrative Cases Concerning Patent Grant and Confirmation - China IP Law Update]]></dc:creator>
		<pubDate>Fri, 18 Sep 2020 22:24:10 +0000</pubDate>
		<guid isPermaLink="false">http://www.chinaiplawupdate.com/?p=231#comment-52</guid>

					<description><![CDATA[[&#8230;] 22(3) (usefulness) and Article 26(3) (enablement) of the Patent Law.  This is to comply with the Phase I Trade Agreement, which stated, &#8220;China shall allow drug patent applicants to rely on supplementary data in the [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] 22(3) (usefulness) and Article 26(3) (enablement) of the Patent Law.  This is to comply with the Phase I Trade Agreement, which stated, &#8220;China shall allow drug patent applicants to rely on supplementary data in the [&#8230;]</p>
]]></content:encoded>
		
			</item>
		<item>
		<title>
		By: Wuhan Institute of Virology Applies for a Patent on Gilead’s Remdesivir - China IP Law Update		</title>
		<link>https://www.chinaiplawupdate.com/2020/01/china-makes-significant-commitments-to-improve-intellectual-property-protection-in-phase-1-trade-deal/#comment-2</link>

		<dc:creator><![CDATA[Wuhan Institute of Virology Applies for a Patent on Gilead’s Remdesivir - China IP Law Update]]></dc:creator>
		<pubDate>Thu, 06 Feb 2020 02:33:05 +0000</pubDate>
		<guid isPermaLink="false">http://www.chinaiplawupdate.com/?p=231#comment-2</guid>

					<description><![CDATA[[&#8230;] Accordingly, as Remdesivir is unavailable in China and chloroquine is, it seems the Institute&#8217;s goal is to enable a cross-license with Gilead and so avoid having the Chinese government invoke compulsory licensing under Articles 48- 50  of the Patent Law, which might cause political repercussions with the U.S. in light on the Phase I trade deal. [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] Accordingly, as Remdesivir is unavailable in China and chloroquine is, it seems the Institute&#8217;s goal is to enable a cross-license with Gilead and so avoid having the Chinese government invoke compulsory licensing under Articles 48- 50  of the Patent Law, which might cause political repercussions with the U.S. in light on the Phase I trade deal. [&#8230;]</p>
]]></content:encoded>
		
			</item>
	</channel>
</rss>